Target intelligence / Profile preview

Mitochondrial chaperone BCS1 (BCS1L)

Target
BCS1L
Molecular classification
Mitochondrial protein, AAA+ ATPase family (ATPases Associated with diverse cellular Activities), Chaperone protein, Mitochondrial respiratory chain complex assembly factor
01

Overview

Mitochondrial chaperone BCS1 (BCS1L) is an essential assembly factor located in the inner mitochondrial membrane, belonging to the AAA+ ATPase family. It plays a critical role in the final steps of mitochondrial respiratory chain complex III (ubiquinol-cytochrome c reductase) assembly by facilitating the insertion of the catalytic Rieske iron-sulfur protein, thereby enabling full enzyme functionality and efficient ATP synthesis through oxidative phosphorylation. Mutations in BCS1L disrupt this process, causing varied mitochondrial diseases—including severe multisystem disorders (GRACILE syndrome) and milder conditions with sensorineural hearing loss (Björnstad syndrome)—characterized by reduced complex III activity, impaired energy production, and multi-organ impairment. BCS1L’s disease spectrum is wide, as its deficiency affects not only ATP synthesis but also leads to oxidative stress and altered iron metabolism, with pathogenic mutations serving as biomarkers for clinical diagnosis[1][2][4][5][6].

Other names
BCS1h-BCS1BCSBJSBCS1-like proteinGRACILE syndrome proteinBjörnstad syndrome proteinMC3DN1PTDFLNMSmitochondrial complex III assembly factorBC1 (ubiquinol-cytochrome c reductase) synthesis-likeBCS1 homologubiquinol-cytochrome c reductase complex chaperone
02

Biological functions

Assembly of mitochondrial respiratory chain complex III (ubiquinol-cytochrome c reductase)Insertion of the Rieske iron-sulfur protein (UQCRFS1) into complex IIIMaintenance of mitochondrial energy production (oxidative phosphorylation, ATP synthesis)Mitochondrial morphology and network maintenance
03

Disease associations

Mitochondrial complex III deficiencyGRACILE syndrome (growth retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis, early death)Björnstad syndrome (sensorineural hearing loss, pili torti)Multisystem mitochondrial disorders (encephalopathy, liver failure, hypotonia, muscle weakness)
04

Safety considerations

Broad phenotypic variability poses diagnostic challengesMulti-organ involvement leads to severe, sometimes lethal syndromesPoor genotype-phenotype correlation for BCS1L mutations
05

Biomarkers

Pathogenic mutations in BCS1L (e.g., S78G, R144Q, V327A, Y301N, R114W)Complex III activity in tissuesAccumulation of Complex III assembly intermediates

Beyond the preview

Go deeper on Mitochondrial chaperone BCS1 (BCS1L).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial chaperone BCS1 (BCS1L).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call